JIC
BMRN icon

Joel Isaacson & Co’s BioMarin Pharmaceuticals BMRN Stock Holding History

Joel Isaacson & Co’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-28
Closed -$2K – 220
2016
Q4 		$2K Buy
+28
New +$2.41K ﹤0.01% 603
2016
Q3 		– Sell
-28
Closed -$2K – 717
2016
Q2 		$2K Hold
28
– – ﹤0.01% 665
2016
Q1 		$2K Hold
28
– – ﹤0.01% 717
2015
Q4 		$3K Buy
+28
New +$2.92K ﹤0.01% 654
2015
Q3 		– Sell
-800
Closed -$107K – 732
2015
Q2 		$109K Hold
800
– – 0.03% 241
2015
Q1 		$100K Hold
800
– – 0.03% 257
2014
Q4 		$72K Buy
+800
New +$66.5K 0.02% 272

Other funds holding BMRN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Joel Isaacson & Co's BMRN Position: Q1 2017 in Review

Joel Isaacson & Co sold out of BioMarin Pharmaceuticals (BMRN) in Q1 2017, closing a stake of 28 shares — an estimated $2K sold.

Joel Isaacson & Co first reported a position in BMRN in Q4 2014 and held it in 7 quarters. The position peaked at $109K in Q2 2015. 418 funds tracked by Wall St. Rank hold BMRN as of Q1 2017.

  • Joel Isaacson & Co reported no remaining BioMarin Pharmaceuticals position as of Q1 2017 after selling out during the quarter.
  • Joel Isaacson & Co sold 28 BioMarin Pharmaceuticals shares in Q1 2017, an estimated $2K.
  • Joel Isaacson & Co first reported a position in BioMarin Pharmaceuticals in Q4 2014 and held it in 7 quarters.
  • Joel Isaacson & Co's BioMarin Pharmaceuticals position peaked at $109K in Q2 2015.
  • 418 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2017.

Based on Joel Isaacson & Co's 13F filing for Q1 2017, filed 5 May 2017.